$BCAC News
Last published 4y ago
- 4y agoBCACApexigen to Participate in the Brookline Capital Markets Newport SymposiumGlobeNewswireSAN CARLOS, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that A
- 4y agoBCACApexigen Announces Board Appointment and New ChairGlobeNewswireSAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen" or the "Company"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today
- 4y agoBCACApexigen Appoints William Duke as Chief Financial OfficerGlobeNewswireSAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the ap
- 4y agoBCACApexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with ChemotherapyGlobeNewswire- Data from the Parker Institute for Cancer Immunotherapy and Cancer Research Institute multi-center Phase 2 PRINCE trial demonstrated that novel circulating and tumor biomarkers may be predictive of overall survival - - Identified distinct immune res
- 4y agoBCACApexigen to Host Investor Day on Antibody Therapeutic Pipeline and Unique APXiMAB™ PlatformGlobeNewswireSAN CARLOS, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that it
- 4y agoBCACRNERSUMRVCKAMoore Kuehn Encourages VCKA, RNER, BCAC, and SUMR Investors to Contact Law FirmPR NewswireNEW YORK, March 24, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to sha
- 4y agoBCACApexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology CompanyGlobeNewswire- Healthcare institutional investors and insiders commit $15 million through private investment in public equity ("PIPE") - - Lincoln Park Capital has committed to purchase up to $50 million of common stock - - Proceeds to advance the
- 5y agoBCACBrookline Capital Markets Hosts Biotech Symposium TodayBusiness WireBrookline Capital Markets is hosting the Brookline Capital Markets Biotech Symposium today at the International Tennis Hall of Fame in Newport, Rhode Island. The theme of the meeting is "Transformative Biotech – Cancer, Rare Diseases, and Viruses."
- 5y agoBCACBrookline Capital Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing February 22, 2021GlobeNewswireNew York, NY, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Brookline Capital Acquisition Corp. (NASDAQ: BCACU) (the “Company”) announced today that, commencing February 22, 2021, holders of the 5,750,000 units...
- 5y agoBCACBrookline Capital Acquisition Corp. Completes Closing of $57,500,000 Initial Public OfferingGlobeNewswireNew York, NY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Brookline Capital Acquisition Corp. (NASDAQ: BCACU) (the “Company”) announced today that it closed its initial public offering of 5,750,000 units,...
- 5y agoBCACBrookline Capital Acquisition Corp. Announces Pricing of $50,000,000 Initial Public OfferingGlobeNewswireNew York, NY, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Brookline Capital Acquisition Corp. (the “Company”) announced today that it priced its initial public offering of 5,000,000 units at $10.00 per unit....